Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2005
11/17/2005WO2005107708A1 Biodegradable intravitreal tyrosine kinase inhibitors implants
11/17/2005WO2005107707A1 Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
11/17/2005WO2005107706A2 Biodegradable intravitreal tyrosine kinase inhibitors implants
11/17/2005WO2005107705A2 Extended therapeutic effect ocular implant treatments
11/17/2005WO2005107703A1 Novel pharmaceutical formulation of cefixime for enhanced bioavailability
11/17/2005WO2005107702A2 Sustained release, mucoadhesive vaginal pharmaceutical compositions
11/17/2005WO2005107669A2 Dressing and method of treatment for a wound
11/17/2005WO2005107668A2 Dressing and method of treatment for a wound
11/17/2005WO2005107660A1 Condom with a coating and composition
11/17/2005WO2005107498A1 Food containing polyphenol
11/17/2005WO2005107470A2 Use of carbonic anhydrase inhibitors for insect control and malaria treatment
11/17/2005WO2005107463A1 Agonists of a2a adenosine receptors for treatment of diabetic nephropathy
11/17/2005WO2005107461A2 Modulating lymphatic function
11/17/2005WO2005096692A3 Crystalline forms of mizolastine, production methods thereof and pharmaceutical compositions containing same
11/17/2005WO2005095401A8 Alpha-trifluoromethyl alcohols or amines as glucocorticoid mimetics
11/17/2005WO2005094385A3 Non-toxic disinfectant containing a isopropyl alcohol and sesame oil composition with lemon oil and menthol
11/17/2005WO2005091967A3 Methods and compositions for ophthalmic treatment of fungal and bacterial infections
11/17/2005WO2005091752A3 Acrylonitrile derivatives for inflammation and immune-related uses
11/17/2005WO2005084654A3 Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
11/17/2005WO2005082353A3 Use of beta-lapachone for treating or preventing cancer
11/17/2005WO2005082337A3 Compositions comprising prodrugs of proton pump inhibitors
11/17/2005WO2005082048A3 Dissolvable film and method of manufacture
11/17/2005WO2005081821A3 Polymorphic forms of 6-11 bicyclic ketolide derivatives
11/17/2005WO2005080890A9 Pharmacologically acceptable salts of clopidogrel
11/17/2005WO2005079319A3 C10 cyclopentyl ester substituted taxanes
11/17/2005WO2005077423A3 Adept or gdept producing acetaldehyde
11/17/2005WO2005073240A3 Novel hiv protease inhibitors
11/17/2005WO2005072361A3 Aminocyclopentyl pyridopyrazinone modulators of chemokine receptor activity
11/17/2005WO2005070427A8 Compounds for the sustained reduction of body weight
11/17/2005WO2005065696A8 Pharmaceutical compositions comprising an extract of euphorbia prostrata
11/17/2005WO2005065266A8 Di-substituted pyrrolotriazine compounds
11/17/2005WO2005060960A3 Use of histamine to treat bone disease
11/17/2005WO2005058834A3 Quinolines useful in treating cardiovascular disease
11/17/2005WO2005058275A3 Ingestible capsules containing ethanol
11/17/2005WO2005058246A3 Method for preparing radiolabeled thymidine
11/17/2005WO2005051906A3 Heterocyclic inhibitors of mek and methods of use thereof
11/17/2005WO2005051396A3 Methods for reducing body fat using vitamin d compounds
11/17/2005WO2005049648A3 Chimeric or fusion constructs of insulin-like growth factor binding proteins as chemotherapeutic agents
11/17/2005WO2005041870A3 Composition and method for the treatment of eye disease
11/17/2005WO2005030751A3 Dipeptidyl peptidase inhibitors
11/17/2005WO2005023204A3 Aromatic prodrugs of propofol, compositions and uses thereof
11/17/2005WO2005020972A3 Combination therapy for the treatment of ocular neovascular disorders
11/17/2005WO2005016270A3 Methods for treatment of dermatological conditions
11/17/2005WO2005016264A3 Diamine derivatives of quinone and uses thereof
11/17/2005WO2005016227A3 Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof
11/17/2005WO2005013908A3 Neuroprotection protects against cellular apoptosis, neural stroke damage, alzheimer’s disease and retinal degeneration
11/17/2005WO2005012242A3 Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
11/17/2005WO2005007096A3 Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator
11/17/2005WO2005007088A3 Stabilized anthocyanin extract from garcinia indica
11/17/2005WO2004108114B1 Anti-fungal composition and a process for its manufacture
11/17/2005WO2004098504A3 Antitumor 2-aminocarbonyl-1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazines and methods of treating tumors
11/17/2005WO2004096208A9 Composition for oral administration containing alkylene dioxybenzene derivative
11/17/2005WO2004084799A3 Pharmaceutical compositions for inhibiting metal ion dependent enzymatic activity and methods for the use thereof
11/17/2005WO2004082602A3 Carboxamide spirohydantoin cgrp receptor antagonists
11/17/2005WO2004078140A3 SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
11/17/2005WO2004040002A3 ARYL PHOSPHATE DERIVATIVES OF d4T HAVING ACTIVITY AGAINST RESISTANT HIV STRAINS
11/17/2005US20050256384 Noninvasive glucose sensor
11/17/2005US20050256336 Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine
11/17/2005US20050256333 4-(3-(2,6-Dimethoxybenzyloxy)phenyl)-4-oxobutyric acid or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis
11/17/2005US20050256317 Reacting a 5-thio-D-aldohexopyranose derivative with a hydroxyaromatic compound in the presence of a phosphine and an azo reagent; Mitsunobu reaction conditions; useful as an sodium-dependent glucose transporter (SGLT2) inhibitor; beta-selective glycosylation
11/17/2005US20050256315 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators
11/17/2005US20050256311 Pyrimidine compounds
11/17/2005US20050256308 Spiro compounds, medicinal compositions containing the same and intermediates of the compounds
11/17/2005US20050256211 Patient oxygenation using stabilized fluorocarbon emulsions
11/17/2005US20050256210 Compounds with activity at estrogen receptors
11/17/2005US20050256209 Psoraleae fructus extracts; administered through topical application, injection, oral administration, or time release dosage form; treating postmenopausal estrogen-deficient osteoporosis without increasing the probability of the subject woman in gaining breast cancer
11/17/2005US20050256208 Pharmaceutical composition containing bakuchiol for treating woman breast cancer
11/17/2005US20050256207 Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
11/17/2005US20050256206 Enantiomers of O-desmethyl venlafaxine
11/17/2005US20050256205 prepared by dissolving Venlafaxine in an organic solvent to form a solution at elevated temperature, adding seeding crystals, cooling the solution, and separating the crystalline polymorph; storage stability
11/17/2005US20050256204 Topical phenyl-epinephrine Rosacea treatment
11/17/2005US20050256203 3-[(1-RS,2-SR)-2-[(dimethylamino)methyl]-1-hydroxycyclohexyl]-benzamide; treating a central nervous system disorder; antinociceptive and analgesic potency and efficacy
11/17/2005US20050256202 reacting a solution of atazanavir in acetone solvent with a concentrated sulfuric acid; need to add the seeds of Form A crystals of atazanavir bisulfate to the reaction mixture; salt formation; Form A crystals; HIV protease inhibitor
11/17/2005US20050256201 Phenethanolamine derivatives
11/17/2005US20050256200 Benzoyl peroxide compositions having increased potency
11/17/2005US20050256199 2-Amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
11/17/2005US20050256198 2-[(4-{3-[benzyl(hexyl)amino]-3-oxopropyl}phenoxy)methyl]benzoic acid;peroxisome proliferator-activated receptors alfa agonist; antidiabetic, hypotensive agent; obesity, elevated VLDL (Very Low Density Lipoproteins) and reduced HDL (High Density Lipoprotein) concentrations
11/17/2005US20050256197 Methods and compositions for facilitating metabolic control
11/17/2005US20050256196 Decreasing brain neuronal glutamate levels using alpha-keto branched chain amino acids
11/17/2005US20050256195 Composition for preventing hypertension
11/17/2005US20050256194 Denaturants for sympathomimetic amine salts
11/17/2005US20050256193 Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
11/17/2005US20050256192 Comprising L-arginine and creatine
11/17/2005US20050256190 Administering a diacylglycerol especially of omega 3 unsaturated fatty acids such as glycerol dilinolenate; also use in processed oil or fat food having insulin resistance improving effect; diabetes
11/17/2005US20050256189 Method of treating dry eye disorders and uveitis
11/17/2005US20050256188 Formulations of anthraquinone derivatives
11/17/2005US20050256187 Method and composition for synergistic topical therapy for neuromuscular pains
11/17/2005US20050256186 Prevention of and countermeasures against mitochondrial disease
11/17/2005US20050256185 Spiro and dispiro 1,2,4-trioxolane antimalarials
11/17/2005US20050256184 1,2,4-Trioxanes and 1,2,4-trioxepanes
11/17/2005US20050256183 Hsp90-inhibiting zearalanol compounds and methods of producing and using same
11/17/2005US20050256182 Formulations of anti-pain agents and methods of using the same
11/17/2005US20050256181 Treating a viral disorder
11/17/2005US20050256180 drugs such as 1 -[4-(aminosulfonyl)phenyl]-8-{[(trifluoromethyl)sulfonyl]amino}-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide, used as antiinflammatory agents, antiarthritic agents, antipyretics or analgesics
11/17/2005US20050256179 Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
11/17/2005US20050256178 Novel nutraceutical compositions comprising boitin
11/17/2005US20050256177 Phenyl derivatives for the treatment of abnormal cell growth
11/17/2005US20050256175 Novel glucagon antagonists/inverse agonists
11/17/2005US20050256174 Raf kinase inhibitors
11/17/2005US20050256172 1-(3-Pyridyl-2-(N-(2-(3,4-dichlorophenyl)ethyl-N-propylamino)ethanol and a dihydrobromide salt; ligands of sigma receptors; sterol Delta 7,8-isomerase inhibitors; anticholesterol agents; antilipemic agents; hypercholesterolemia and hyperlipemia; side effect reduction due to more targeted action
1 ... 4464 4465 4466 4467 4468 4469 4470 4471 4472 4473 4474 4475 4476 4477 4478 4479 4480 4481 4482 4483 4484 ... 7860